Coronary/Structural Heart

FDA Grants Fast Track Designation to Arena Pharmaceuticals’ APD418 for Development in Decompensated Heart Failure Patients

– APD418 currently in Phase 1 clinical investigation – data expected this year SAN DIEGO, Jan. 16, 2020 /PRNewswire/ — Arena Pharmaceuticals, Inc. (Nasdaq: ARNA) today announced that the U.S. Food and Drug Administration (FDA) granted Fast Track designation for APD418, a β3-adrenergic receptor (AdrR) antagonist and cardiac myotrope, in development for the treatment of […]

Neovasc Receives Administrative Acceptance Review Notification for Premarket Approval Application from FDA for the Neovasc Reducer™

VANCOUVER, Jan. 15, 2020 (GLOBE NEWSWIRE) — via NEWMEDIAWIRE – Neovasc Inc. (“Neovasc” or the “Company”) (NASDAQ, TSX: NVCN), a leader in the development of minimally invasive transcatheter mitral valve replacement technologies and in the development of minimally invasive devices for the treatment of refractory angina, today announced receipt of an Administrative Acceptance […]

AngioSoma Acquires Technology Related to 15 Patents

Houston, Jan. 15, 2020 (GLOBE NEWSWIRE) — via NEWMEDIAWIRE — AngioSoma Inc. (OTC: SOAN) (“AngioSoma” or the “Company”) is pleased to announce that we have acquired the unconditional ownership of the following intellectual property and the exclusive right to develop, formulate and market: ·         Method and Composition for Reducing Dysfunction in Angioplasty […]

PhaseBio Announces Acquisition of Novel Oral Aldosterone Synthase Inhibitor to Develop for Treatment-Resistant Hypertension

PhaseBio to be responsible for all development, manufacturing and commercialization MALVERN, Pa. and SAN DIEGO, Jan. 13, 2020 (GLOBE NEWSWIRE) — PhaseBio Pharmaceuticals, Inc. (Nasdaq: PHAS), a clinical-stage biopharmaceutical company focused on the development and commercialization of novel therapies for cardiopulmonary diseases, today announced that it has signed an agreement […]

Biocardia Announces FDA Clearance for Morph DNA Deflectable Guide Catheter

SAN CARLOS, Calif., Jan. 14, 2020 (GLOBE NEWSWIRE) — BioCardia®, Inc. [OTC: BCDA], a leader in the development of comprehensive solutions for cardiovascular regenerative therapies, today announced the U.S. Food and Drug Administration (FDA) has granted 510(k) clearance for the Morph® DNA deflectable guide catheter used to guide the Helix™ Biotherapeutic Delivery System […]

IDTechEx Report Discusses Diagnosing Cardiovascular Disease

BOSTON, Jan. 13, 2020 /PRNewswire/ — Diagnosing CVD is the first step in patients’ road to recovery. It is imperative to detect the disease early in order to administer treatment while it is still treatable. In addition, preventing the disease altogether is becoming more important in healthcare. The main approaches for detecting CVD are […]

BIOTRONIK Launches PK Papyrus Covered Coronary Stent in the US

Lifesaving Solution Now Available Nationwide for Treatment of Acute Coronary Artery Perforations LAKE OSWEGO, Ore., April 10, 2019 /PRNewswire/ — BIOTRONIK today announced the United States (US) commercial launch of the PK Papyrus® covered coronary stent system for use in the emergency treatment of acute coronary perforations.1,2 More than 800,000 percutaneous coronary intervention procedures are performed annually […]

Abbott to Initiate Trial to Study MitraClip as an Option for Moderate Surgical Risk Patients

– New clinical trial will assess first-of-its-kind MitraClip™ transcatheter mitral valve repair against current standard of care surgery in a new, expanded patient population – If successful, the REPAIR MR study has potential to expand MitraClip’s current indication (patients at prohibitive risk for surgery) to also include patients at moderate […]

Resverlogix Confirms a Significant Corporate Advancement Establishing Apabetalone as a Potential Blockbuster Combination Drug in High-risk Diabetes Patients with CVD

BETonMACE Results Show 57% Hazard Reduction in Primary MACE for Patients on Apabetalone and New Oral Anti-Diabetic Treatments CALGARY, Alberta, Jan. 13, 2020 (GLOBE NEWSWIRE) — Resverlogix Corp. (“Resverlogix” or the “Company”) (TSX: RVX) is pleased to announce today additional highly significant findings and clear synergy when apabetalone is combined […]

First Japanese Patients Randomized In Corvia Medical’s REDUCE LAP-HF II Global Clinical Trial For Heart Failure

Pivotal study investigates the Corvia InterAtrial Shunt Device (IASD®) for heart failure TEWKSBURY, Mass., Jan. 13, 2020 /PRNewswire/ — Corvia Medical, Inc., a privately-held company with a first-in-class structural heart device to treat heart failure, today announced the first Japanese patients were randomized in Toyama and Hyogo under a clinical trial authorization […]